Patent ID: 11953503
Assignee: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH
Field: Measurement (Instruments)
Classification: CPC G | IPC G

Claim 0:
1. A method for quantitatively determining a therapeutic tumor necrosis factor (TNF)-alpha inhibitor in a sample, the method comprising the steps of:
a) contacting the sample
with isolated, free TNF-alpha protein to provide a reaction mixture;

b) incubating the reaction mixture to allow binding of the isolated, free TNF-alpha protein to therapeutic TNF-alpha inhibitor in the sample;
c) contacting the incubated reaction mixture with a first TNF-alpha binding partner to allow formation of a complex of isolated, free TNF-alpha protein remaining after step b) with the first TNF-alpha binding partner;
d) determining the amount of the complex composed of TNF-alpha protein and the first TNF-alpha binding partner; and
e) determining the amount of the therapeutic TNF-alpha inhibitor in the sample by comparing the amount of the complex composed of TNF-alpha protein and the first TNF-alpha binding partner determined in step d) with amounts of a complex composed of TNF-alpha protein and the first TNF-alpha binding partner in reaction mixtures containing samples having known concentrations of a TNF-alpha inhibitor.